Linde vs LyondellBasell Industries
LIN and LYB side by side, both in chemicals and allied products. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How LIN and LYB compare
Linde is the larger company, worth 12 times as much as LyondellBasell Industries ($242B against $20.2B).
Linde grew revenue faster over the last twelve months (8.2% versus 3.5% for LyondellBasell Industries).
Both pay dividends: Linde yields 1.2% and LyondellBasell Industries 5.5%.
LyondellBasell Industries scores higher on the StockData Score (15 against 14 for Linde), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | LIN | LYB |
|---|---|---|
| Size and price | ||
| Market cap | $242B | $20.2B |
| Share price | $526.55 | $62.58 |
| Change, 1 year | 25.2% | 46.3% |
| Change, 5 years | 58.5% | −30.0% |
| Beta (5Y) | 0.58 | 0.65 |
| Employees | 65K | 19K |
| StockData Score | ||
| Total score | 14 | 15 (better) |
| Valuation score | 0 | 3 (better) |
| Growth score | 2 | 2 |
| Performance score | 5 (better) | 1 |
| Health score | 3 | 4 (better) |
| Dividend score | 4 | 5 (better) |
| Valuation | ||
| P/E | 35.0× | – |
| P/S | 6.7× | 0.6× (better) |
| P/B | 6.1× | 1.8× (better) |
| EV/EBITDA | 20.5× | 6.5× (better) |
| P/FCF | 47.6× | 8.4× (better) |
| PEG | 1.66 | – |
| FCF yield | 2.1% | 11.9% (better) |
| Fair value | $417.12 | $90.68 |
| Margin of safety | −26.2% | 31.0% (better) |
| Growth | ||
| Revenue growth (TTM) | 8.2% (better) | 3.5% |
| Revenue growth, 5Y average | 4.5% (better) | 1.7% |
| Net income growth (TTM) | −1.2% | – |
| EPS growth (TTM) | 0.87% | – |
| EPS growth, 5Y average | 25.4% | – |
| Profitability | ||
| Gross margin | 47.9% (better) | 14.3% |
| Operating margin | 25.3% (better) | 8.6% |
| Net margin | 19.3% | – |
| FCF margin | 14.0% (better) | 7.6% |
| Return on equity | 18.0% | – |
| Return on invested capital | 11.5% (better) | 11.1% |
| Financial health | ||
| Debt / equity | 0.68 (better) | 1.10 |
| Net debt / EBITDA | 1.75 | 1.67 (better) |
| Interest coverage | 35.5× (better) | 5.1× |
| Current ratio | 0.86 | 1.78 (better) |
| Altman Z-score | 4.12 (better) | 2.19 |
| Piotroski F-score | 7 | – |
| Dividends and buybacks | ||
| Dividend yield | 1.2% | 5.5% (better) |
| Payout ratio | 41.6% | – |
| Years of dividend growth | 9 | 12 (better) |
| Dividend growth, 5Y average | 9.3% (better) | 5.3% |
| Buyback yield | 1.7% (better) | 0.00% |
| Shareholder yield | 2.8% | 5.5% (better) |
| Ownership | ||
| Held by institutions | 85.7% | 75.0% |
| Held by insiders | 0.20% | 20.0% |
| Insider net buying, 12 months | −$62.0M | −$27.0M (better) |
| Superinvestors holding | 6 (better) | 2 |
| Short interest, % of float | 1.5% | 4.2% |
Go deeper
- LIN stock overview
- LIN income statement
- LIN valuation and score
- LYB stock overview
- LYB income statement
- LYB valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.